INCY Incyte Genomics Inc Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
17:15
04 авг
04 авг
Earnings beat with expanding drug pipeline.
Incyte reported Q4 revenue of $1.67B and adjusted earnings of $3.09, crushing the $2.12 estimate, and raised full-year net sales guidance. The company, once seen as a one-drug name, now has a pipeline of 9–10 drugs in various stages of trials, all of which could be major winners. Technically, traders can watch the $109 area (50-day) as an alert, investors can use the 200-day near $101, with the uptrend over above $100.
Выс.
11:35
29 июл
29 июл
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks.
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks including ABBV, KO, and F in a broad round of analyst upgrades.
12:00
28 июл
28 июл
The overall guidance tone is confident with raised revenue guidance for the year, reflecting broad-based strength across the portfolio and a stronger pipeline.
Выс.
20:12
19 июн
19 июн
Спикер отмечает, что INCY активно ищет возможности для приобретения в сфере иммунологии.
Спикер отмечает, что INCY активно ищет возможности для приобретения в сфере иммунологии, указывая на NKTR как на потенциальную цель; прямой прогноз по INCY не озвучен.
Низ.
15:38
08 июн
08 июн
Incyte CEO confirmed the company is actively seeking I&I bolt-on acquisitions.
Incyte CEO confirmed the company is actively seeking I&I bolt-on acquisitions; mentioned as potential acquirer of NKTR, no direct directional view on INCY itself stated.
Сред.
11:42
08 июн
08 июн
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its.
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its hematology portfolio into bleeding disorders.
12:00
28 апр
28 апр
Management conveys strong confidence in the company's trajectory, with net sales up 20%, a strong pipeline, and multiple upcoming regulatory milestones. The tone is optimistic, and they reaffirm full-year guidance while highlighting the potential of new product launches.
Выс.
01:10
08 мар
08 мар
The failure to win a key FDA label expansion is a direct negative catalyst for the stock.
The failure to win a key FDA label expansion is a direct negative catalyst for the stock, impacting future revenue streams.
Сред.
08:24
20 фев
20 фев
The trade is long Incyte based on the continued strength of its ruxolitinib franchise.
The trade is long Incyte based on the continued strength of its ruxolitinib franchise and strong expected sales growth for its drug Opzelura.
Сред.
13:00
10 фев
10 фев
Management guided revenues up 10-13% and emphasized multiple late-stage pipeline catalysts (Monjuvi, Povacitinib, KRAS G12D, etc.) that could triple the top line. The long-term strategy to replace the Jackify franchise with diversified core growth underpins the bullish tone.
Выс.
Об аналитическом покрытии INCY
Buzzberg отслеживает INCY (Incyte Genomics Inc) в 6 источниках. Бычьих сигналов: 1, медвежьих: 0, от 6 аналитиков. Сентимент преимущественно бычий (9%). Всего отслеживается 11 торговых идей. За последние 7 дней: бычьих: 1, наблюдение: 1. Последние спикеры: Josh Brown, DeItaone, Bill.